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Melanoma cells rely on developmental programs during tumor initiation and progression.
Here we show that the embryonic stem cell (ESC) factor Sall4 is re-expressed in the
Tyr::NrasQ61K; Cdkn2a−/− melanoma model and that its expression is necessary for primary
melanoma formation. Surprisingly, while Sall4 loss prevents tumor formation, it promotes
micrometastases to distant organs in this melanoma-prone mouse model. Transcriptional
profiling and in vitro assays using human melanoma cells demonstrate that SALL4 loss
induces a phenotype switch and the acquisition of an invasive phenotype. We show that
SALL4 negatively regulates invasiveness through interaction with the histone deacetylase
(HDAC) 2 and direct co-binding to a set of invasiveness genes. Consequently, SALL4 knock
down, as well as HDAC inhibition, promote the expression of an invasive signature, while
inhibition of histone acetylation partially reverts the invasiveness program induced by SALL4
loss. Thus, SALL4 appears to regulate phenotype switching in melanoma through an HDAC2-
mediated mechanism.
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General hallmarks of cancer include genetic mutations andchromosomal rearrangements1. To sustain growth andeventually progress to metastatic disease, tumors undergo
several additional molecular changes including epigenetic rewir-
ing and altered transcription of specific genes2,3. The aberrant re-
expression of genes reminiscent of the embryonic cell-of-origin
and the hijacking of its transcriptional programs have been
identified as possible drivers of cancer progression4–6. In different
cancer types, stem-cell-like cancer cells have been associated with
tumor initiation, sustained growth, and metastasis formation7.
Furthermore, the reacquisition of features reminiscent of stem
cells has been associated with reduced anticancer immunity,
resistance to different therapies and disease relapse8–10.
Cutaneous melanoma is the most aggressive skin cancer due to
its high metastatic potential11. The embryonic cell-of origin of
melanocytes, from which melanoma arises, is the neural crest
stem cell (NCSC)12. Melanoma cells are known to hijack neural
crest (NC)-related migratory programs during tumor initiation,
invasion, and metastasis formation13–18. For instance, the tran-
scription factors PAX3, FOXD3, and SOX10 are part of a gene
regulatory network in early NC development that also supports
melanoma cell growth, migration, and resistance to targeted
therapy, respectively. Furthermore, the transcription factor YY1
has recently been shown to control comparable metabolic path-
ways in NC and melanoma cells and to be equally required for
both development and melanoma formation19. Likewise, the
neurotrophin receptor CD271/NGFR/p75NTR, which marks
migratory NCSCs, is re-expressed in melanoma cells and renders
them more invasive, metastatic, and therapy resistant13,15,20,21
and of note, transient ectopic expression of NGFR was shown to
promote phenotype switching—the dynamic transition of mela-
noma cells from a proliferative to a highly invasive state22–24.
Here we identify the stem cell factor SALL4 as a regulator of
melanoma phenotype switching. We find that Sall4 is the stron-
gest upregulated transcription factor in hyperplastic, melanoma-
prone murine melanocytes when compared to normal wild-type
melanocytes and that Sall4 is crucial for primary melanoma
growth. SALL4 is a known embryonic stem cell (ESC) regulator25
and its aberrant re-expression has been reported for an increasing
number of cancer types, such as germ cell tumors, hepatocellular
carcinoma, gastric cancer, leukemia-, and others26. Due to its re-
expression in cancers, SALL4 has been dubbed an ‘oncofetal’
gene27. Since such genes are not expressed in adult tissues except
for malignant lesions, factors such as SALL4 represent ideal tar-
gets for cancer diagnosis and disease treatment27,28. However, in
the present study, we show that while upregulation of Sall4 is
crucial to sustain melanoma tumor growth, its depletion or
downregulation increases invasiveness and metastasis formation
in melanoma. Intriguingly, SALL4 appears to regulate a
melanoma-specific invasion program through HDAC2-mediated
epigenetic silencing of invasiveness genes.
Results
Sall4 is re-expressed in hyperplastic murine melanocytes. To
identify factors essentially involved in melanoma tumorigenesis,
we analyzed RNA sequencing data previously obtained19 from
wild-type melanocytes and hyperplastic melanocytes isolated
from the skin of 3-months-old Tyr::NrasQ61K; Cdkn2a−/− mice
(Fig. 1a). Loss of the tumor suppressor Cdkn2a together with gain
of Nras function in the melanocytic lineage of these mice leads to
hyperplastic melanocytes already at birth and primary melanoma
arising around the age of 6 months29. When comparing hyper-
plastic to wild-type melanocytes by RNA sequencing (RNA seq)
(Supplementary Data 1), we found among the top 20 upregulated
genes one transcription factor, Sall4 (logFC 9.59, p value < 0.0001)
(Fig. 1b). Upregulation of Sall4 in hyperplastic versus wild-type
melanocytes was confirmed by immunohistochemistry on mouse
skin sections (Fig. 1c). Moreover, murine primary melanoma
displayed prominent Sall4 expression (Supplementary Fig. 1).
Likewise, we could not detect SALL4 expression in melanocytes of
healthy human skin, in agreement with a previous study30, while
SALL4 was strongly expressed in human melanoma tissue
(Supplementary Fig. 2a, b).
Conditional knockout of Sall4 in the melanocytic lineage leads
to reduced primary melanoma formation. Given the re-
expression of Sall4 in hyperplastic melanocytic lesions, we next
addressed whether Sall4 is essential for melanoma formation. We
therefore crossed the Tyr::NrasQ61K; Cdkn2a−/− melanoma mouse
model31,32 with inducible Tyr::CreERT2 33 and Sall4lox/lox 34 and
R26R-LSL-GFPmice35 (Fig. 2a). By doing so, we obtained a mouse
model that spontaneously developed melanoma, in which Sall4
could be deleted in melanocytes upon tamoxifen (TM) injections
(Fig. 2b) and Cre activity could be traced by GFP expression
(Supplementary Fig. 3a). We assessed Sall4 expression levels in
this model by mRNA analysis of isolated melanocytes from
recombined postnatal day 8 mice of either wild-type (Tyr::CreERT2
LSL-R26R-GFP or -tdTomato), Sall4+/− conditional knockout
(cko) (Tyr::NRasQ61K Cdkn2a−/− Tyr::CreERT2 Sall4lox/wt LSL-
R26R-GFP or -tdTomato), or Sall4−/− cko (Tyr::NRasQ61K Cdkn2a
−/− Tyr::CreERT2 Sall4lox/lox LSL-R26R-GFP or -tdTomato) geno-
types (Supplementary Fig. 3b). Hyperplastic melanocytes exhibited
more than 10-fold increased Sall4 levels compared to wild-type
melanocytes while Sall4 levels gradually decreased upon condi-
tional knockout of Sall4 alleles, with Sall4−/− cko melanocytes
having Sall4 expression levels comparable to wild-type melano-
cytes (Supplementary Fig. 3b). Interestingly, when we compared
the numbers of primary melanomas in adult Sall4 control and
Sall4−/− cko mice, we found that upon Sall4 ablation, primary
tumor formation was impaired (Fig. 2c, d). Heterozygous Sall4+/−
cko mice displayed no phenotype in comparison to control ani-
mals in regard to primary tumor numbers (Fig. 2c, d). However,
Sall4+/− cko tumors were characterized by a decreased pro-
liferation rate compared to Sall4 wild-type primary tumors
(Fig. 2e; Supplementary Fig. 3c).
Sall4 loss results in an increased metastatic burden in vivo. In
addition to proliferation, SALL4 has been associated with
increased migration and invasion of solid tumors other than
melanoma36–38. Therefore, we assessed whether loss of Sall4
affects melanoma metastasis formation in our melanoma-
susceptible mouse model. For this purpose, we quantified the
formation of lung micrometastases traced by GFP expression in
Sall4−/− cko and Sall4+/− cko animals (Fig. 2f, g, h; Supple-
mentary Fig. 4a, b). Melanoma identity of the micrometastases
was confirmed by immunohistochemical staining for the mela-
nocyte marker MITF (Fig. 2g). Strikingly, we found a significant
increase in micrometastases counts in Sall4−/− cko as well as in
Sall4+/− cko mice compared to the control animals (Fig. 2h).
These data suggest that in melanoma—similar to other cancer
types—Sall4 is essential for tumor growth, while its depletion or
downregulation leads to increased micrometastases formation,
which is in contrast to its function observed in other cancer
types36–38.
SALL4 promotes proliferation and suppresses invasion in
human melanoma cells. To validate the findings from our mouse
model in human melanoma cells, we carried out siRNA-mediated
SALL4 knockdown experiments in various human melanoma cell
lines with different mutational backgrounds. Namely, M010817
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(NRASQ61K-mutated), M070302 (unknown mutation status),
M150548 (BRAFV600E-mutated), MM150536 (BRAFV600E-muta-
ted), WM1361A (NRASQ61R and PTEN +/−-mutated), and
M121224 (NRASQ61K- and BRAFV600E-mutated) cells were sub-
jected to different experimental setups to address aspects of
proliferation, tumor growth, migration, and invasion (Fig. 3).
After validation of knockdown efficiency of SALL4 on mRNA
and protein levels (Fig. 3a–c), cell proliferation upon SALL4
knockdown was assessed using the xCELLigence® Real-Time Cell
Analysis (RTCA) DP Instrument. The human melanoma cell
lines tested displayed decreased proliferation capacities after
SALL4 knockdown (Fig. 3d–f; Supplementary Fig. 5a, b). To test
whether knocking down SALL4 would also lead to decreased
tumor growth of human xenografts in vivo, we next injected
human melanoma cells 24 h after siRNA transfection sub-
cutaneously into nude mice and analyzed tumor growth within
6 days after grafting. In line with our previous findings, the
majority of assessed siSALL4-treated human melanoma cells
showed reduced growth capacities in vivo (Fig. 3g, h). Since our
transgenic mouse model had indicated a role of Sall4 in tumor
growth as well as in micrometastasis formation, we next analyzed
melanoma cell migration and invasion in regards to SALL4
expression. First, to address whether cell intrinsic migratory
capacities correlate with SALL4 levels, human melanoma cells
were subjected to a Corning Transwell® migration assay (Sup-
plementary Fig. 5c). Interestingly, we found that migratory cells
from two of three cell lines tested expressed significantly less
SALL4 than nonmigratory cells of the same cell lines (Supple-
mentary Fig. 5d). Second, to assess whether reduced SALL4
expression functionally leads to increased invasiveness, human
melanoma cells treated with siSALL4 or siControl were seeded
into Corning Transwell® invasion chambers wherein a porous
membrane is coated with a matrigel layer through which the cells
have to invade. Cells that had passed through the matrigel-coated
membrane to the other side of the membrane (invasive cells) were
stained with DAPI and analyzed. Consistent with our previous
results, all three siSALL4-treated human melanoma cell lines
tested showed a significantly increased invasion capacity com-
pared to siControl-treated cells (Fig. 3i–k).
SALL4 negatively regulates a set of melanoma-specific inva-
siveness genes. To determine the molecular mechanism by which
SALL4 loss leads to increased invasion, we performed RNA seq
on siControl and siSALL4-treated M010817 cells and found 1004
genes significantly upregulated and 1140 genes significantly
downregulated in siSALL4 over siControl samples (Fig. 4a; Sup-
plementary Data 2). Gene ontology (GO) analysis with Meta-
Core™ revealed that the upregulated genes were strongly enriched
in Process Networks related to cell adhesion/cytoskeleton,
developmental processes related to epithelial-to-mesenchymal
transition, angiogenesis, and others (Fig. 4b; Supplementary
Data 2). Oppositely, the downregulated genes were enriched in
Process Networks related to cell cycle regulation, inflammation,
and developmental processes such as hedgehog signaling or
melanocyte differentiation (Fig. 4c; Supplementary Data 2). The
differential gene expression obtained upon SALL4 knockdown
pointed towards an upregulation of EMT-related genes and a
downregulation of differentiation genes, overall suggesting
acquisition of a transcriptional signature typical of melanoma cell
phenotype switching. To assess whether there was a significant
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Fig. 1 Sall4 is upregulated in hyperplastic melanocytes. a Experimental scheme of isolated melanocytes for RNA sequencing either from Tyr::CreERT2;
R26R-LSL-tdTomato wild-type mice or Tyr::CreERT2; R26R-LSL-tdTomato; Tyr::NrasQ61K; Cdkn2a−/− mice with hyperplastic, melanoma-prone skin. At the age
of 4 months, the mice were injected on 5 consecutive days with 80 µg g−1 body weight tamoxifen to induce tdTomato expression in melanocytes. The hair
growth cycle in wild-type animals was synchronized by dorsal hair plucking. Melanocytes were isolated from mouse back skin of wild-type and melanoma
model mice (3–6 mice per sample) and FACS sorted for cKit (staining) and tdTomato (endogenous). b Row z-score heatmap of normalized counts from
RNA sequencing as illustrated in a. Visualized are the top 20 most upregulated genes comparing hyperplastic (Tyr::NrasQ61K; Cdkn2a−/−) to wild-type
melanocytes. Genes are ordered top to bottom with genes with highest LogFC values on top. Cutoffs were set at p values < 0.05 and FDR < 0.05. Sall4
(LogFC value = 9.59) represents the only and hence highest upregulated transcription factor within those top 20 upregulated genes. The complete list of
all differentially expressed genes can be found under Supplementary Data 1. c Immunohistochemical staining of wild-type melanocytes in murine hair
follicles (left panel) and melanoma-prone melanocytes in hyperplastic Tyr::NrasQ61K; Cdkn2a−/− mouse skin (right panel). Arrowheads point towards wild-
type melanocytes with undetectable Sall4 expression; arrows point towards hyperplastic and rare wild-type melanocytes with detectable Sall4 protein.
Experiment has been repeated independently three times with similar results. Scale bars 25 µm.
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enrichment in genes related to phenotype switching among our
differentially expressed genes upon siSALL4, we carried out Gene
Set Enrichment Analysis (GSEA)39, where the ranked
siSALL4 signature was compared to published melanoma phe-
notype switching signatures. We found that SALL4-regulated
genes showed a significant enrichment and positive correlation
with published invasiveness signatures40–42, while they sig-
nificantly anti-correlated with their corresponding proliferation
signatures40–42 (Fig. 4d). Next, siSALL4-mediated upregulation of
a set of invasiveness genes representing the top enriched Meta-
Core™ Process Networks and also the published melanoma phe-
notype switching signatures (bold genes in Fig. 4b, c) was
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validated by qRT-PCR in the five previously used human cell
lines (Fig. 4e) and, for selected gene products, by immunocy-
tochemistry and western blot in M010817 cells (Supplementary
Fig. 6a, b). Together, our data suggest that the reduced expression
of SALL4 induces human melanoma cell invasion via upregula-
tion of known melanoma invasiveness genes, which could explain
the increased metastasis burden seen upon Sall4 loss in the
Tyr::NrasQ61K; Cdkn2a−/− melanoma mouse model.
SALL4 and HDAC2 interact and directly regulate a set of
target genes. SALL4 has been shown to regulate transcription by
a variety of different mechanisms26. In mouse ESCs for example,
Sall4 has been shown to exert stemness regulatory function via
direct binding and activation of a distal enhancer of the gene
Pou5f1, which encodes the pluripotency regulator Oct425. Fur-
thermore, in adult human CD34+ hematopoietic stem cells, a
whole set of direct targets of SALL4 has been identified by
Chromatin Immunoprecipitation (ChIP)-chip and additional
ChIP-qPCR validation43. Interestingly, neither POU5F1 nor the
16 validated genes (except for HN1) from Gao et al., (2013b) were
significantly changed in our RNA sequencing upon SALL4
knockdown in melanoma cells. Similarly, MYC has previously
been shown to be a direct target of SALL4 in endometrial
cancer38, but we could not detect any altered MYC expression
upon SALL4 knockdown. We therefore hypothesized that
in melanoma SALL4 might exert its regulatory function in an
alternative manner and have a different array of target genes.
It has previously been reported that SALL4 can interact with
epigenetic co-factors both in stem cells as well as in cancerous
cells26. One type of epigenetic enzymes that has been shown to
interact with SALL4 are histone deacetylases (HDACs), specifi-
cally HDAC1 and HDAC228,44,45, which are part of the
Nucleosome Remodeling Complex (NuRD)46. Since HDAC1,
HDAC2, and HDAC3 have been reported to be overexpressed in
melanoma cells compared to primary melanocytes47, we
addressed whether in human melanoma cells, SALL4 can interact
with one of the HDACs. By Co-immunoprecipitation (Co-IP)
experiments we detected protein interaction between SALL4 and
HDAC2 in the human melanoma cell line M010817 (Fig. 5a;
Supplementary Fig. 7), which led to the hypothesis that SALL4
might repress invasiveness genes via recruitment of histone
deacetylases, leading to epigenetic silencing of target genes such
as invasiveness genes. To test this idea and address which genes
are directly bound by both SALL4 and HDAC2, we carried out a
cleavage under targets and release using nuclease (CUT&RUN)
sequencing experiment for SALL4 as well as for HDAC2. Of note,
we chose to perform CUT&RUN with two different antibodies
per factor, each set consisting of one antibody that had previously
been published for CUT&RUN or ChIP sequencing plus one
additional one (Supplementary Data 3). To determine target
genes of both SALL4 and HDAC2, we performed peak calling
with SEACR for loci that contained significant peaks with at least
3 of the 4 antibodies used (Fig. 5b, c, d; Supplementary Data 4).
The ‘3of4’ antibody approach allowed us on one hand to
strengthen the specificity of the SALL4-HDAC2 targets and on
the other hand to identify novel peaks that might only be
recognized by one or another antibody due to epitope masking in
protein complexes at specific locations. Interestingly, several of
the identified SALL4-HDAC2 peaks were associated with putative
invasiveness genes, with peaks either at the transcription start site
(TSS) (such as for VEGFR-1) (Fig. 5e), downstream of the TSS
(such as for TGFBR2) (Fig. 5f), or within annotated putative
regulatory elements (such as for PDGFC, CDH2 (N-cadherin),
and FN1) (Fig. 5g–i). The fact that these genes were upregulated
upon SALL4 depletion (Fig. 4b, e) and direct targets of both
SALL4 and HDAC2 is consistent with the idea that SALL4
recruits HDAC2 to these specific loci, resulting in histone
deacetylation and hence repression of these invasiveness-related
target genes.
Next, we analyzed with HOMER the DNA binding motifs of the
CUT&RUN peaks that are unique for SALL4 (Supplementary
Figs. 8, 9, 10), unique for HDAC2 (Supplementary Figs. 11, 12, 13),
and most importantly, the DNA binding motifs that are
shared between SALL4 and HDAC2 (Supplementary Fig. 14).
Interestingly, we found amongst our top SALL4-HDAC2 shared de
novo DNA binding motifs matches for known transcriptional
regulators of the NC that are re-expressed and have functional
implication in melanoma, such as SOX10 and SOX948 or
RUNX149,50, and also key regulators of melanocyte differentiation
and hence melanoma, such as MITF51 or TFAP2C52,53 (Fig. 5j).
This further strengthens the hypothesis that SALL4 and HDAC2
together regulate melanocyte and melanoma-specific cellular
processes.
Differentially expressed SALL4-HDAC2 targets enrich in cell
adhesion-related processes. Since we had found that SALL4 and
HDAC2 bind to a large set of common loci, we wanted to cor-
relate their direct targets with differential expression upon SALL4
knockdown. As we hypothesized that SALL4 recruits HDAC2 to
specific loci to repress gene activity, we assessed which SALL4-
HDAC2 targets (peaks with at least 3 of 4 SALL4-HDAC2 anti-
bodies) were significantly upregulated after SALL4 knockdown
Fig. 2 Sall4 is essential for primary tumor formation, but its depletion leads to increased micrometastasis. a Genetics scheme of the Tyr::NrasQ61K;
Cdkn2a−/− transgenic mouse model spontaneously developing melanoma, which was crossed with inducible Tyr:CreERT2; Sall4lox/lox; R26R-LSL-GFP mice,
allowing ablation of Sall4 from the melanocytic lineage upon tamoxifen administration. b Experimental scheme depicting how at 1 month of age the
experimental mice from a undergo Cre-mediated recombination due to 5 consecutive i.p. tamoxifen injections. Hyperplasia gradually develops from birth of
the pups. Primary tumors and metastasis were assessed at around 6 months of age. c Photographs of control and heterozygous (Sall4lox/wt; termed Sall4+/−
cko) and homozygous (Sall4lox/lox; termed Sall4−/− cko) Sall4 cko animals (left panel). Hematoxylin and eosin staining of back skin from respective control,
Sall4+/− cko or Sall4−/− cko animals (right panel), which has been repeated in independent experiments with similar results 7 times. Scale bars 500 µm. d
Quantification of primary tumor numbers of control (Sall4+/+ and non-tamoxifen-injected animals), Sall4+/− cko and Sall4−/− cko animals. e Quantification
of proliferation rate, assessed by immunohistochemistry (see Supplementary Fig. 3c), in primary tumors of control and Sall4+/− cko animals. f Binocular
images of mouse lungs. The endogenous fluorescent GFP signal was imaged under a fluorescent binocular and for visualization inverted and set to black/
white (B/W). Dark spots therefore represent inverted GFP+ spots set to B/W. Scale bars 500 µm. g Immunohistochemical stainings of mouse lung sections
to verify melanoma identity of GFP+ spots by means of MITF expression. Scale bars top panel 100 µm, second and third panel 25 µm. h Quantification of GFP
+ lung metastases of tamoxifen-injected control (Sall4+/+), Sall4+/− cko, and Sall4−/− cko animals. Metastasis score= 0 indicates <5 GFP+ lesions, 1 >5
lesions, 2 >20 lesions, 3 >50 lesions, 4 >100 lesions. In d, e, h, error bars represent mean ± SEM with N indicated in the respective figures. Two-sided t-tests
between groups were performed for significance with p values ≥0.05= n.s.; <0.05= *; <0.01= **, with Sall4−/− cko in d P= 0.0049; Sall4+/− cko in e
P= 0.0456; Sall4+/− cko in h P= 0.0011; Sall4−/− cko in h P= 0.0129. Source data for d, e, h are provided as a Source Data file.
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(RNA Seq) and found 184 direct SALL4-HDAC2 targets with
increased expression upon SALL4 KD (Fig. 6a; Supplementary
Data 4). MetaCore™ Process Network enrichment analysis
revealed that these targets were associated with cell adhesion,
TGFβ signaling, angiogenesis, and EMT (Fig. 6b; Supplementary
Data 4). For instance, among the SALL4-HDAC2 targets upre-
gulated upon SALL4 knockdown, we found integrins (ITGB1,
ITGA6, ITGA4), N-cadherin (CDH2), TGFBR2, VEGFR-1,
PDGFC, LOXL2, MAPK8, and many others which are associated
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Data 4). These results strongly support our hypothesis that SALL4
and HDAC2 co-repress invasiveness genes in melanoma and that
either SALL4 or HDAC inhibition induces their expression.
We next analyzed the SALL4-HDAC2 target genes that were
downregulated upon SALL4 loss (Supplementary Fig. 15a;
Supplementary Data 4). Of note, MetaCore™ analysis showed
that in general the Process Network enrichment of the siSALL4
downregulated direct SALL4-HDAC2 targets was less significant
and processes were represented by fewer genes (Supplementary
Fig. 15b) than was the case for the siSALL4 upregulated direct
SALL4-HDAC2 targets (Fig. 6b). Nevertheless, of interest, the top
enriched process of siSALL4 downregulated direct SALL4-
HDAC2 targets was related to melanocyte differentiation,
represented by downregulated direct targets such as MITF,
DCT, β-catenin (CTNNB1), and tyrosinase (TYR), among others
(Supplementary Fig. 15b). These data suggest that melanocyte
differentiation genes, although they can be bound by SALL4-
HDAC2, are subject to positive regulation by SALL4 by a
mechanism that remains to be elucidated. Possibly, transcrip-
tional activation in these cases might involve tertiary co-factors
recruited to SALL4-HDAC2 target loci. To address this, we
reanalyzed the SALL4-HDAC2 peaks within melanocyte differ-
entiation genes (Supplementary Data 5) using CIIIDER to predict
transcription factors (TFs) significantly enriched at these peaks
(Supplementary Data 5). The resulting list of TFs (Supplementary
Data 5) putatively bound to the same loci as SALL4 and HDAC2
was filtered for high stringency and further analyzed with
STRING to predict protein–protein interactions with SALL4
(Supplementary Fig. 15c, red cluster). Interestingly, this in silico
approach revealed TFs regulating NC development and mela-
noma as putative SALL4 binding partners at melanocyte
differentiation gene loci with joint SALL4 and HDAC2 peaks
such as TFAP2A (Supplementary Fig. 15c, red cluster), a well-
known transcriptional activator in NC cells54,55 and a regulator of
melanocyte differentiation genes53. Hence, our data raise the
possibility that amongst others, TFAP2A can be recruited to
SALL4-HDAC2-target elements of melanocyte differentiation
genes and that SALL4 (and possibly HDAC2) loss leads to a loss
in TFAP2A-mediated transcriptional activation of these genes
even if HDAC2-mediated repression is attenuated after
SALL4 loss.
We also elaborated on genes that might putatively be regulated
exclusively by either SALL4 or HDAC2 by screening for protein-
coding genes that only show CUT&RUN peaks with the two
SALL4 antibodies the two HDAC2 antibodies, respectively, but
no 3 of 4 shared peaks (Supplementary Data 6). By doing so, we
found that genes exclusively bound by SALL4 enrich in biological
processes related to neurogenesis, neurophysiological processes,
and others, while genes exclusively bound by HDAC2 enriched in
various different process classes such as immune cell adhesion,
cell cycle, apoptosis, and developmental processes (Supplemen-
tary Data 6). These data suggest that SALL4 largely relies on the
interaction with HDAC2 to negatively regulate invasiveness genes
in melanoma.
To functionally strengthen this hypothesis, we inhibited
HDACs in human melanoma cell lines with HDAC inhibitors
(HDACi) for 48 h and measured gene expression by qRT-PCR
(Fig. 6c). Specifically, treatment with the class I HDACi
inhibitor Mocetinostat, which inhibits HDACs 1, 2, and 3,
resulted in a differential gene expression pattern similar to SALL4
knockdown, in that invasiveness genes were upregulated, while
melanocyte differentiation genes were downregulated (Fig. 6c). A
similar, although less striking effect was detected after treatment
with the pan-HDAC inhibitor Panobinostat (Fig. 6c). Impor-
tantly, phenotypically HDACi treatment led to increased invasion
in vitro for the majority of tested human melanoma cell lines
(Fig. 6d, e).
These findings are in accordance with our results that showed
increased invasiveness of melanoma cells upon SALL4 loss
(Fig. 3i–k) and with previous studies that have reported HDAC
inhibitor-induced invasiveness in melanoma cells and other
cancer cells56,57. We therefore further addressed the expression of
invasiveness genes in HDACi-treated melanoma cells in vivo.
Human melanoma xenografts in athymic nude mice were treated
with Mocetinostat and Panobinostat (Supplementary Fig. 16a)
and tumor lysates were analyzed for expression of invasiveness
genes at the experimental endpoint. While mice treated with
either Panobinostat or Mocetinostat showed reduced xenograft
tumor growth (Supplementary Fig. 16b), the expression of
established invasiveness genes, such as AXL or NGFR was
upregulated (Supplementary Fig. 16c). Moreover, we detected a
trend of reduced expression of melanocyte differentiation genes,
such as MITF, MLANA, or DCT, in the lysates of HDACi-treated
tumors (Supplementary Fig. 16c).
SALL4 knockdown leads to differential histone acetylation in
invasiveness genes. Given that SALL4-HDAC2 target genes
belonging to invasiveness processes are upregulated upon SALL4
loss or HDAC inhibition, we wanted to assess whether SALL4
regulates epigenetic activation of invasiveness genes in general.
Since HDACs catalyze deacetylation of histones and, conse-
quently, transcriptional repression of target genes58,59, we
Fig. 3 SALL4 knockdown leads to reduced proliferation and increased invasion. a–c SALL4 expression after 48 h knockdown with two different siRNAs
assessed by western blot (top panel and bottom panel left (quantification)) and qRT-PCR (bottom panel right) on the same samples. Experiments
performed in human melanoma cells with different mutational backgrounds: M010817 (NRASQ61K), M070302 (unknown mutational status), M150548
(BRAFV600E). siS4: siSALL4. d–f xCELLigence real-time analysis of cell proliferation (Cell Index) of M010817, M070302, and M150548 cells after 48 h
siRNA-mediated SALL4 knockdown as in a–c. Three samples per experimental group were analyzed, each consisting of four technical replicas (proliferation
wells analyzed by xCELLigence). g–h In vivo xenografts after SALL4 knockdown: 24 h after siRNA treatment in vitro, cells were grafted subcutaneously onto
nude mice and let grown for 6 days, when images were taken and tumor sizes of M010817 and M150548-derived grafts were quantified. Scale
units= 1 mm. i–k Corning Transwell® invasion assay: siControl or siSALL4-treated cells (48 h) were seeded onto the porous, matrigel-covered membrane
of an invasion chamber insert and let to migrate from FCS-free (top chamber) to FCS high (lower chamber) medium. Numbers of invaded cells on the
bottom side of the invasion membrane were analyzed after 24 h. Invaded cells were stained with DAPI, imaged and set to black and white (top panels) for
quantification (bottom panels). Scale bars 200 µm. Error bars represent mean ± SD and for significance, two-sided t-tests were performed with N= 3 (a–f)
and N= 4 (g–k) and p values ≥0.05= n.s.; <0.05= *; <0.01= ** and <0.001= *** with siRNA#1 in a (lower left panel) P= 0.0001; siRNA#2 in a (lower
left panel) P= 0.0015; siRNA#1 in a (lower right panel) P= 0.0099; siRNA#2 in a (lower right panel) P= 0.0476; siRNA#1 in b (lower left panel)
P= 0.0070; siRNA#2 in b (lower left panel) P= 0.0133; siRNA#1 in b (lower right panel) P= 0.0006; siRNA#2 in b (lower right panel) P= 0.0058;
siRNA#2 in c (lower left panel) P= 0.0094; siRNA#1 in c (lower right panel) P= 0.0016; siRNA#2 in c (lower right panel) P= 0.0129; siRNA#1 in
g P= 0.0372; siRNA#2 in g P= 0.0047; siRNA#1 in h P= 0.0117; P in i= 0.0009; P in j= 0.0012; P in k= 0.0129. Source data for all panels are provided
as a Source Data file.
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Fig. 4 RNA sequencing of SALL4 knockdown reveals an invasiveness gene expression signature. a RNA seq row z-score heatmap of differentially
expressed (DE) genes after 48 h SALL4 knockdown in the human cell line M010817. Cutoffs were set at Log2 ratio≥ 0.27 or ≤−0.27, p value < 0.05 and
FDR < 0.05 and resulted in 1004 genes significantly upregulated and 1140 genes significantly downregulated. b Top 12 MetaCoreTM process networks of
upregulated genes. Top ten most upregulated genes per process are listed and genes validated in additional cell lines are highlighted in bold. c Top 12
MetaCoreTM process networks of downregulated genes. Top ten most downregulated genes per process are listed and genes validated in additional cell
lines are highlighted in bold. d Gene Set Enrichment Analysis (GSEA) of DE genes after SALL4 knockdown (log2 ratio-ranked) as in a with published
genesets characterizing invasive versus proliferative melanoma cells40–42. e Log2 expression ratio heatmap of qRT-PCR-based gene expression analysis of
specific genes of interest (normalized to PPIA and set relative to siCtrl-treated cells) in human melanoma cell lines (M010817: NRASQ61K; M070302:
unknown mutational status; M150548: BRAFV600E; M121224: NRASQ61K and BRAFV600E; MM150536: BRAFV600E) after 48 h treatment with two different
siRNAs targeting SALL4. Two-sided t-tests were performed with N= 3 and p values≥ 0.05= n.s. Source data for e are provided as a Source Data file.
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hypothesized that SALL4 knockdown would lead to derepression
and increased acetylation of target genes associated with inva-
siveness. To address this hypothesis, we performed an H3K27ac
Chromatin Immunoprecipitation sequencing (ChIP-seq) experi-
ment of cells treated with siCtrl or siSALL4 (Supplementary
Data 7) to identify genes with differential histone acetylation
upon SALL4 knockdown (Fig. 7a, Supplementary Data 8).
Overall, we found more gained H3K27ac peaks than lost ones
upon SALL4 knockdown (Fig. 7a, b). Most of the peaks were
annotated to intron and intergenic regions or promotor/
a











































































Rank Motif p-value % of
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2 1e-291 59.57% SOX10
3 1e-221 35.01% SOX9
4 1e-129 21.69 % AML1 (RUNX1)
5 1e-128 19.67 % AP-2 gamma(TFAP2C)
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transcription start sites (TSS) (Fig. 7b), such as for the invasive-
ness genes VEGFR-1, FN1, PDGFC, and NGFR (promoter) or
AXL (upstream), which showed significantly gained H3K27ac
peaks (Fig. 7c–g, red bars and red, dashed highlighting) mediated
by SALL4 knockdown, while no significantly lost H3K27ac peaks
were found at the presented tracks.
Since we had hypothesized that increased histone acetylation in
siSALL4 cells can partially be linked to reduced SALL4-mediated
HDAC2 recruitment to specific target genes (i.e., invasiveness
genes), we next wanted to address whether differential acetylation
patterns can indeed be detected upon SALL4 knockdown at loci
bound by both SALL4 and HDAC2. In line with our hypothesis,
differential acetylation ChIP-seq peaks were present within 10 Kb
intervals of the SALL4-HDAC2 peaks, as determined by means of
a read density heatmap (Fig. 7h). Thus, H3K27ac is differentially
regulated within a fraction of the SALL4-HDAC2-bound loci.
Moreover, when we correlated the loci bound by SALL4-HDAC2
and showing increased H3K27ac ChIP-seq peaks in siSALL4
(Fig. 7h) with increased RNA expression after SALL4 knockdown
(Fig. 4b, Supplementary Data 2), we again found, among others,
invasiveness genes such as TGFBR2, ITGA6, or VEGFR-1
(Supplementary Data 9), that were enriched in biological
processes related to cell adhesion, TGFβ signaling, and others
(Supplementary Data 9).
Of importance, the heatmap correlating SALL4-HDAC2
targets with differential acetylation (Fig. 7h) also revealed that a
large fraction of SALL4-HDAC2 peaks likely regulate more
distant regulatory elements and not the exact same loci, to which
the two proteins directly bind. This is to be expected due to the
fact that any genomic locus that becomes functionally proximal to
the SALL4/HDAC2 protein duet—which could also happen via
genomic looping of far distant regulatory regions—could be
differentially acetylated by HDAC2. Therefore, as it is difficult to
define the exact genomic loci that the SALL4/HDAC2 complex
regulates, we decided to investigate the functional impact of
SALL4-recruited HDAC2 on a genome-wide level by correlating
the regions of differential acetylation with the genes differentially
expressed after SALL4 knockdown (Fig. 7i, Supplementary
Fig. 17a). To do so, we restricted our H3K27ac ChIP-seq analysis
to proximity to TSS by exclusively analyzing changed peaks
within −15/+10 kb of the TSS. We found significantly gained
H3K27ac peaks in 2566 genes and significantly lost H3K27ac
peaks in 1131 genes (Supplementary Data 8). Next, we did an
overlay of the genes with significantly gained or lost H3K27ac
marks and increased or decreased transcription based on RNA
seq, respectively. Within the more than 2000 genes with gained
H3K27ac marks, 261 genes also showed increased mRNA levels
(Fig. 7i, Supplementary Data 8), while within the more than 1000
genes with lost H3K27ac levels, 137 genes showed decreased
mRNA expression (Supplementary Fig. 17a, Supplementary
Data 8). Interestingly, among the 261 genes with gained
H3K27ac and increased transcription, we could again identify
invasiveness genes such as VEGFR-1, PDGFC, ITGA6, NGFR,
AXL, FN1, SERPINE1, among others, and MetaCore™ process
network enrichment again resulted in pathways related to cell
adhesion, EMT, angiogenesis, and others (Fig. 7j).
GSEA on the 398 genes with gained or lost histone acetylation
and increased or decreased expression, respectively, (combined
from Fig. 7i and Supplementary Fig. 17a) confirmed a positive
correlation of the siSALL4 signature with the invasiveness
signature of Verfaillie and colleagues (2015), while it showed a
negative correlation with the corresponding proliferation signa-
ture (Fig. 7k), further suggesting that downmodulation of SALL4
changes the activating chromatin mark H3K27ac of genes related
to phenotype switching.
Of note, while we hypothesize that SALL4 knockdown leads to
derepression of invasiveness genes through attenuated HDAC2-
mediated target gene repression, epigenetic activation of target
genes after SALL4 loss could be boosted by direct targets of
SALL4 and HDAC2 that function as epigenetic activators. For
instance, we found the lysine demethylase 4 C (KDM4C) or the
lysine acetyltransferase 2B (KAT2B) as direct targets of SALL4
and HDAC2 (Supplementary Fig. 18a, b), which have been
identified as SALL4 targets in other systems as well60,61. Hence,
upregulation of invasiveness genes after SALL4 depletion might
be induced by a joint epigenetic mechanism of lost repression and
gained activation of target genes.
To further test whether siSALL4-mediated upregulation of
invasiveness genes was indeed dependent on differential acetyla-
tion, we combined SALL4 knockdown with an inhibitor of
histone acetyl transferases (HATs), CTK7A, and quantified the
expression of invasiveness genes. Of note, upregulation of
invasiveness genes, such as ITGA6, FLT1 (VEGFR-1), PDGFC,
FN1, NGFR, AXL, ETS1, and others, could be significantly
rescued by addition of the HAT inhibitor CTK7A (Supplemen-
tary Fig. 19a-c), supporting our hypothesis that SALL4 regulates
melanoma invasiveness genes via chromatin modulating mechan-
isms involving histone deacetylation.
Discussion
SALL4 is a member of the spalt-like (SALL) gene family, which
are the vertebrate homologues of the developmental spalt (sal)
genes in Drosophila62. Sall4 is a zinc finger transcription factor
that plays an essential role in maintaining pluripotency and self-
renewal of ESCs by regulating Pou5f1 and by direct binding to
Nanog and Oct425,63. Sall4 is vastly expressed during murine
embryonic development and of note, in a previous study we have
detected its expression also in murine neural crest stem cells19. In
the adult, however, Sall4 is mostly absent and detectable only in
the germ cells of the ovaries or testis64. Similarly to mice, SALL4
Fig. 5 SALL4 and HDAC2 interact and have a set of common target genes in melanoma cells. a Western blot for SALL4 and HDAC2 after Co-
Immunoprecipitation (Co-IP) with a SALL4 antibody in the human melanoma cells M010817. Experiment has been repeated independently with similar results
two times. b CUT&RUN (C&R) in M010817 cells with two antibodies against SALL4 (SALL4_Ab#1 (S_Ab#1) and SALL4_Ab#2 (S_Ab#2)) and two antibodies
against HDAC2 (HDAC2_Ab#1 (H_Ab#1) and HDAC2_Ab#2 (H_Ab#2)) and Ctrl (anti-FLAG) visualized as read density heatmaps of the centered peaks
(within 10 kb) for all loci showing peaks with at least 3 of the 4 (2x SALL4, 2x HDAC2) antibodies. c C&R peak numbers called with SEACR for single antibodies,
shared between antibodies and shared between at least 3 of the 4 SALL4-HDAC2 antibodies. In total 3319 loci contained peaks for at least 3 of 4 antibodies
tested and were found in total 2301 different genes. Those peaks were used for further analyses correlating the direct targets with either expression (Fig. 6a, b) or
acetylation status (Fig. 7h). d Annotation of C&R peaks to genetic regions. Green: the 5019 SALL4_Ab#1 and SALL4_Ab#2 shared peaks; yellow: the 1925
HDAC2_Ab#1 and HDAC2_Ab#2 shared peaks; grey: the 3319 peaks shared between at least 3 of the 4 SALL4_Ab#1, SALL4_Ab#2, HDAC2_Ab#1, and
HDAC2_Ab#2 antibodies. TTS: transcription termination site, TSS: transcription start site, UTR: untranslated region. e–i Specific gene tracks visualized with IGV.
Green: SALL4_Ab#1 and SALL4_Ab#2; yellow; HDAC2_Ab#1, and HDAC2_Ab#2. Red dashed lines highlight significantly called peaks (with at least 3 of 4
antibodies). j Selected de novo DNA binding motifs of SALL4-HDAC2 (at least 3 of 4 antibodies) shared peaks analyzed by HOMER. Source data for a and d are
provided as a Source Data file.
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expression in adult human tissue is thought to be restricted to
testis and ovaries64 and hematopoietic stem/progenitor cells
(HSPCs)43.
Several studies have reported the re-expression of the stem cell
factor SALL4 in the adult in different cancer types26. Mostly, the
re-expression of SALL4 was associated with increased tumor cell
proliferation and decreased patient survival. Here, we show that
Sall4 is upregulated in hyperplastic murine melanoma-prone
melanocytes and that its expression is essential for melanoma
primary tumor growth. However, in contrast to previous studies
on other cancer types, our results reveal that depletion of Sall4 in
a murine melanoma model leads to increased micrometastasis
formation while preventing sustained tumor growth. In line with
these in vivo results, knockdown of SALL4 in human melanoma
cells leads to reduced tumor cell proliferation and to the upre-
gulation of a set of well-known melanoma invasiveness
genes, inducing an invasive cell phenotype. Hence, our findings
identify SALL4 as a negative regulator of melanoma cell
d e 
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Fig. 6 SALL4-HDAC2 targets that are upregulated after SALL4 depletion or HDAC inhibition enrich in invasion-related processes. a Significantly
upregulated genes after SALL4 knockdown (Fig. 4a, b) were overlaid with the C&R data of direct SALL4-HDAC2 targets (Fig. 5b, c), which resulted in 184
direct SALL4-HDAC2 targets significantly upregulated after SALL4 knockdown. b MetaCore™ Process Network enrichment of the 184 direct targets from
a. The top 12 most significant processes are given with the specific genes of each process listed in red. Genes that were validated for DE in other cell lines
are highlighted in bold. c Log2 fold change heatmap of qRT-PCR-based gene expression (normalized to PPIA and set relative to vehicle (DMSO)-treated
samples) after 48 h cell treatment with the HDAC inhibitors Mocetinostat (0.6 µM) and Panobinostat (7 nM). t-tests were performed for significance
between HDACi and vehicle-treated groups with N= 3 and p values≥ 0.05= not significant (n.s.). d Images of DAPI-stained nuclei in invasion assays as in
Fig. 3 i–k. Cells were seeded into the invasion chamber, which was supplemented with vehicle or 600 nM Mocetinostat or 7 nM Panobinostat in both the
starvation as well as the FCS high medium. After 24 h, the invaded cells were analyzed by counting DAPI-stained nuclei of invaded cells at the bottom of
the membrane (inverted and set to black and white (B/W)). Scale bars 200 µm. e Quantification of invaded cells in d set relative to control cells. Moce:
mocetinostat, Pano: panobinostat. Error bars represent mean ± SD in e. For significance, two-sided t-tests were performed with N= 3 (c) and N= 4 (e) and
p values ≥0.05= n.s.; <0.05= *; <0.01= **; and <0.001= *** with Moce in e (top panel) P= 0.0218; Moce in e (middle panel) P= 0.0051; Pano in
e (middle panel) P= 0.0463; Moce in e (lower panel) P= 0.0332; Pano in e (lower panel) P= 0.0051. Source data for c and e are provided as a Source
Data file.
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phenotype switching, i.e. the reversible change from a high pro-
liferative/low invasive to a low proliferative/high invasive cell
state23,24,40. Notably, SALL4 negatively controls melanoma
invasiveness-related genes, as for instance NGFR, a potent reg-
ulator of phenotype switching22, FN1, VEGFR-1, CDH2 (N-
cadherin), and other genes implicated in melanoma invasiveness.
The binding of SALL4 to chromatin and epigenetic modifier
enzymes and the resulting epigenetic rewiring of target genes has
previously been shown in ESCs as well as in cancer. Amongst the
published epigenetic co-factors of SALL4 are DNA methyl-
transferases (DNMT-1, DNMT-3A, DNMT-3B, and DNMT-3L),
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based on tandem mass spectrometry studies on ESCs and
293 T cells overexpressing SALL4, it has been shown that SALL4
can also bind to the NuRD complex members HDAC1 and
HDAC245. Here we show that SALL4 can build a protein complex
together with HDAC2 also in human melanoma cells and that
SALL4 and HDAC2 together directly bind to genes involved in
melanocyte and melanoma biology, such as VEGFR-1, CDH2 (N-
cadherin), FN1, TGFBR2, MITF, and others.
Strengthening the hypothesis that SALL4-HDAC2 epigeneti-
cally repress transcriptional activity of invasiveness genes,
knockdown of SALL4 leads to increased H3K27 acetylation and
increased transcription of melanoma invasiveness-related genes,
such as FN1, VEGFR-1, PDGFC, and NGFR, which could be
partially rescued by administration of a histone acetyltransferase
(HAT) inhibitor. Likewise, HDAC inhibition with two different
HDAC inhibitors, leads to upregulation of a similar set of
invasiveness-related genes and to increased invasiveness in vitro.
This supports the hypothesis that SALL4 inhibits invasiveness-
related genes in melanoma via interaction with HDACs. HDAC
inhibitors have been considered for usage in combinatorial
therapies for several cancers including melanoma47,65–67. Our
data suggest caution in the use of these inhibitors because of
potential adverse, metastasis-promoting effects of HDAC inhi-
bitors in melanoma patients.
Others have shown different sets of target genes epigenetically
silenced by SALL4. Lu et al (2009), for instance, identified by
ChIP the SALL4 targets SALL1 and PTEN. Since the binding sites
of those target genes were co-occupied by NuRD components
with HDAC activity, the authors argued that SALL4 silences
PTEN and SALL1 by interacting with NuRD. Phenotypically, the
decreased expression of the tumor suppressor PTEN in SALL4
transgenic mice was associated with myeloid leukemia and cystic
kidneys45. Indeed, in our experiments, binding of SALL4 and
HDAC2 to PTEN (but not SALL1) was confirmed by CUT&RUN
(Supplementary Data 3 and 4). However, we did neither observe
differential acetylation patterns in ChIP-seq nor transcriptional
changes in RNA seq of PTEN or SALL1 upon SALL4 knockdown.
In addition, other previously identified direct targets of SALL443
have not come up in our analyses either, which suggests that
SALL4 might regulate a set of specific targets in melanoma cells.
Regarding melanoma disease progression, there is increasing
evidence that the re-expression of NCSC-related factors can
regulate melanoma initiation and later stages of the disease, such
as resistance to therapies or invasion and metastatic spread16.
However, unlike melanoma cells undergoing phenotype switch-
ing, NCSCs during embryonic development continue to pro-
liferate when they migrate and invade distant tissues68.
Intriguingly, while some NCSC factors, such as SOX10 and YY1,
are activated upon melanoma formation and are required for
melanoma growth16,19,29,69, other NCSC-associated factors, such
as CD271/NGFR/p75NTR, PAX3, and FOXD3 promote
melanoma cell invasiveness and metastasis formation22,70. This
suggests that the embryonic program active in NCSCs segregates
in melanoma to regulate distinct aspects of phenotype switching,
namely proliferation vs. invasion. Our study adds SALL4 to the
growing list of stem cell factors known to control melanoma cell
biology16. Similar to SOX10 and YY1, SALL4 is upregulated in
melanoma cells and is essential for primary tumor formation and
proliferation. Importantly, however, SALL4 depletion in mela-
noma leads to increased invasiveness and micrometastasis for-
mation. This is reminiscent of melanoma cells displaying reduced
SOX10 levels, which is associated with increased expression of
SOX9, another factor involved in NC development, and increased
invasiveness48,71. Thus, it will be important to elucidate to what
extent the gene regulatory program of NCSCs is functionally
implicated in mediating cellular plasticity during melanoma dis-
ease progression. Knowledge of this program might allow defin-
ing strategies targeting both tumor growth and metastasis
formation.
Methods
Transgenic mice and in vivo TM application. Tyr::NrasQ61K animals and
Cdkn2a-deficient mice have been described previously31,32. Also the Tyr::CreERT2
murine line33, Sall4lox mice34, and R26R-LSL-GFP mice35 have been analyzed
previously. Mice were bred and crossed in-house to generate the Tyr::NrasQ61K;
Tyr::CreERT2; Sall4lox/lox; R26R-LSL-GFP genotype and resulted in a mixed genetic
background. All animal breeding, housing and experimentation was conducted
according to the guidelines of the veterinary office of the Canton of Zurich,
Switzerland. Specifically, animals were housed in a controlled environment with a
12 h light/dark cycle, with free access to water and food and at temperatures of
21–23 °C and humidity of 40–60%. Genotyping was performed on toe or ear
biopsies, followed by PCR on isolated DNA using the Taq PCR Core Kit (201225,
Qiagen) and primers as listed in Supplementary Table 2. For conditional ablation
of Sall4, 8-weeks-old transgenic mice of both genders were injected intraper-
itoneally (i.p.) with 100 µl tamoxifen (TM) (T5648, Sigma–Aldrich) diluted in
ethanol and sunflower oil (1:9 ratio) at a concentration of 1 mg d−1 for 5 days
according to an established protocol29. Melanoma-developing mice were mon-
itored and euthanized at an endpoint defined by adverse clinical symptoms, such as
multiple skin tumors Ø >5 mm, weight loss (4m> 15%) or a hunched back. All
animal experiments have been approved by the veterinary authorities of Canton of
Zurich, Switzerland and were performed in accordance with Swiss law.
Quantification of skin melanomas and metastases. At sacrifice of the animals,
skin melanomas and metastasis were assessed. Above a diameter of 2 mm
(Ø > 2mm), developing trunk skin lesions were considered as melanomas. The
tumors of the heterozygous cko group were verified to have been recombined and
lost Sall4 by either GFP or Sall4 immunohistochemical stainings of tumor sections.
Animals with non-recombined tumors were excluded from the analysis. The
Control group consisted of noninjected Tyr::NrasQ61K Cdkn2a−/− Tyr::CreERT2
Sall4lox/lox R26R::GFP and TM-injected Tyr::NrasQ61K Cdkn2a−/− Tyr::CreERT2
Sall4wt/wt R26R::GFP animals for analysis of primary tumor numbers and of TM-
injected Tyr::NrasQ61K Cdkn2a−/− Tyr::CreERT2 Sall4wt/wt R26R::GFP animals for
analysis of lung metastases. To assess whether GFP+ spots in the mouse lungs were
of melanoma identity, MITF and GFP co-stainings were performed on histological
sections of the mouse lungs. For quantification of micrometastasis, the number of
GFP+ spots in the lungs were categorized as follows: <5 lesions= score 0; >5
lesions= score 1; >20 lesions= score 2; >50 lesions= score 3; >100 lesions= score
4. Group sizes are indicated for each experiment in the respective figures.
Fig. 7 SALL4 can regulate invasiveness genes through an epigenetic mechanism. a Read density heatmap of gained and lost H3K27ac ChIP sequencing
peaks (±2 kb) upon SALL4 knockdown (left panels) and average read distribution of gained and lost H3K27ac peaks within ±5 kb from peak center (right
panels). b Distribution of the gained and lost H3K27ac peaks in different genetic regions. TTS: transcription termination site, TSS: transcription start site,
UTR: untranslated region. c–g Representative tracks of invasiveness genes with significantly gained (red bars; highlighted by red, dashed lines) H3K27ac
peaks in siSALL4 over siCtrl (no significantly lost H3K27ac peaks were detected for the visualized gene tracks). h Read density heatmap of differential
H3K27ac ChIP-seq peaks (within 10 kb) in siSALL4 over siCtrl at direct target genes of SALL4-HDAC2 (CUT&RUN peaks with at least 3 of 4 SALL4/
HDAC2 antibodies). i Significantly upregulated genes after SALL4 knockdown (Fig. 4a, b) were overlaid with those genes that have significantly gained
H3K27ac marks −15/+10 kb of TSS (a, ocher panel). This resulted in 261 genes with activating chromatin marks that were at the same time upregulated
after SALL4 knockdown. j MetaCore™ Process Network enrichment of the 261 genes from i. The top 12 most significant processes are indicated with the
specific genes of each process listed in red. k Gene Set Enrichment Analysis (GSEA) of the combined 261 upregulated (i) and 137 downregulated genes
(Supplementary Fig. 17a) with differential acetylation after SALL4 knockdown (ranked according to log2 expression ratio of RNA seq results) with the
previously published melanoma programs of Verfaillie and colleagues (2015). Source data for b are provided as a Source Data file.
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Melanocyte isolation from neonate murine skin and qRT-PCR. For isolation of
reporter-traced melanocytes, recombination of neonate mice was achieved by
injecting the breast-feeding mother i.p. with TM as described before29 one day after
birth of the offspring and for 5 consecutive days. Tissue of neonate mice was
harvested as follows. Mice were euthanized by decapitation and trunk back skin
was dissected, cut into small pieces and incubated in DMEM/F12 (Gibco
21041025) with 10% FCS and 1.5 mg/ml Collagenase Type I (Merck SCR103) and
1:1000 Protector RNase Inhibitor (Roche 3335399001) for 1 h at 37 °C on a shaker.
The digested tissue was next spun down at 1200 rpm for 5 min, and the pellet
resuspended in complete DMEM/F12. To make a single-cell suspension, the
solution was next pushed three times through an 18 G needle (Sterican 4665120)
and next, five times through a 21 G Needle (Sterican 304432). The single-cell
suspension was then filtered through a 40 µm cell strainer and centrifuged with
400 × g for 5 min at 4 °C. The pellet was resuspended in DMEM/F12 with 10% and
1mM EDTA and 1:1000 RNase Inhibitor and cells sorted by means of FACS on a
BD FACSAria™ III Cell Sorter (BD Biosciences). Sorted cells were next subjected to
RNA isolation performed with the Direct-zol™ RNA MiniPrep Kit (ZYMO
Research, R2050) according to the manufacturer’s instructions. A total of 500 ng
isolated RNA was reverse transcribed using Maxima First Strand cDNA Synthesis
Kit (K1641, Thermo Scientific) according to the manufacturer’s recommendations.
Real-time quantitative PCR (qRT-PCR) was performed on a LightCycler 480
System (Roche) using LightCycler 480 SYBR Green I Master (4707516001, Roche)
with technical triplicates for each sample.
Immunohistochemical stainings. After dissection, mouse tissue samples were
washed in PBS (Thermo Fisher, 10010) and fixed in 4% Roti Histofix (Carl Roth,
P087.3) overnight at 4 °C. Next, samples were embedded in paraffin and cut into
sections of 5 µm. Samples were then deparaffinized and either stained for hema-
toxylin and eosin according to standard procedures or stained for immuno-
fluorescence as follows. Sections were subjected to microwave-based antigen
retrieval using in-house made Citrate Buffer. After washing slides with PBS, they
were blocked for one hour at room temperature in blocking buffer containing 1%
BSA (Sigma–Aldrich, 05470) and 0.2% Tween (Sigma–Aldrich, P1379) in PBS.
After washing in PBS, primary antibodies were applied in blocking buffer at the
concentrations indicated in Supplementary Table 3 and incubated at 4 °C over-
night. After washing the sections again in PBS, they were incubated with secondary
antibodies in blocking buffer for 1 h at room temperature (RT). Finally, Nuclei
were stained with Hoechst 33342 (Sigma–Aldrich, 14533) and slides were mounted
with Fluorescent Mounting Medium (Dako, S3023). Immunohistochemical and
fluorescent sections were imaged with either the Mirax Midi Slide Scanner (Zeiss)
or a DMI 6000B microscope (Leica). Murine hyperplastic skin and primary tumors
in Supplementary Fig. 1 and human healthy melanocytes and primary melanoma
in Supplementary Fig. 2 were stained accordingly: After deparaffinization of the
sections as described above, an antigen retrieval step was performed using citrate
buffer (S2369, Dako). Prior to blocking, the endogenous peroxidase activity was
quenched using 3% Hydrogen Peroxide Solution for 1 h at RT and the sections
were permeabilized and blocked in blocking buffer (1% BSA in PBS and 0.05%
Triton X-100) for 15 min at RT. The Sall4 staining was amplified using tyramide
superBoost Kit (Thermo Fisher, Cat# B40926). As secondary antibodies, a biotin-
coupled antibody (Jackson Immuno Research, 711-065-152, 1:100) and
streptavidin-HRP (Jackson Immuno Research, 016-030-084, 1:100) were used.
Multiplexing was performed by stripping off the Sall4 primary antibody. The
sections were immersed in citrate buffer (S2369, Dako) and stripping was per-
formed using the HistosPRO machine (Milestone, SW2.0.0) for antigen retrieval at
100 °C for 20 min. The sections were blocked another time in blocking buffer for
15 min at RT prior to application of the Sox10 homemade antibody in blocking
buffer overnight at 4 °C. Samples were mounted in Fluorescent Mounting Medium
(Dako, S3023) and imaged using Zeiss Axio Scan. Z1.
Human cell lines. Cells used for experiments were either provided by the Uni-
versity Hospital Zurich where surplus tumor material was obtained after surgical
removal of melanoma metastases from patients after written informed consent and
approved by the local IRB (EK647 and EK800) or commercially acquired (A375
and WM1361A). Medical staff at the University Hospital Zurich confirmed the
melanoma diagnosis of the tumor material by histology and immunohistochem-
istry. The selective adherence method of Raaijmakers et al. (2015)72 was used to
establish primary melanoma cell cultures from patient biopsies. All primary mel-
anoma cell lines are also included in the URPP biobank, University Hospital
Zürich, Department of Dermatology. Cells were grown and cultured for experi-
ments in RPMI 1640 (Sigma Life Science, USA) supplemented with 10% fetal
bovine serum (Gibco, Life Technologies, USA), 4 mM l-Glutamine (25030, Life
Technologies), and a mix of penicillin–streptomycin antibiotics (15070, Life
Technologies). Work with human melanoma cells was approved by the local ethical
review board (KEK Nr. 2014-0425). Detailed information about the cell lines can be
found in Supplementary Table 1.
siRNA transfection. Cells were cultured in starvation medium (0.5% FCS) and
after 24 h transfected at 60% confluency in complete growth medium (RPMI 1640
with 10% FCS, 4 mM L-Glutamine, Pen-Strep) with a final siRNA concentration as
indicated in Supplementary Table 4. For transfection, the JetPrime transfection kit
(114, Polyplus transfection) was used according to the manufacturer’s guidelines.
Further information on siSALL4#1 and #2 can be found in Supplementary Table 4.
RNA isolation and real-time PCR. RNA extraction and DNase treatment of
samples was performed using the ReliaPrep™ RNA Miniprep kit (Promega, Z6010)
according to manufacturer’s guidelines. Purified RNA was quantified using
nanodrop and subjected to reverse transcriptase reaction using Maxima First
Strand cDNA Synthesis Kit (K1641, Thermo Scientific) according to manu-
facturer’s recommendations. Real-time quantitative PCR (qRT-PCR) was per-
formed on a LightCycler 480 System (Roche) using LightCycler 480 SYBR Green I
Master (4707516001, Roche). Primers used for qRT-PCR are listed in Supple-
mentary Table 2. Each sample was analyzed in technical triplicates on the Light-
Cycler 480 device (Roche) and relative quantified RNA was normalized to
housekeeping gene transcripts as indicated for each figure.
Protein isolation and western blotting. Cultured cells were lysed and protein
extracted as described previously22. Protein concentrations were determined with
the BCA Protein Assay Kit (#23227, Thermo Fisher Scientific) using a DTX 880
Multimode Detector at 562 nm. Thirty micrograms of total protein were run
through Mini-PROTEAN® TGX™ Precast Gels (Bio-Rad) and transferred onto
nitrocellulose membranes (Bio-Rad, 2895), which were stained with primary
antibodies in Odyssey blocking buffer (LI-COR Biosciences, 927–40000) overnight
at 4 °C and visualized using secondary antibodies in Odyssey blocking buffer for
45 min at RT . Blots were scanned and quantified with an Odyssey imaging system
(LI-COR Biosciences).
xCELLigence real-time cell proliferation analysis. For assessment of cell pro-
liferation, we made use of the xCELLigence® Real-Time Cell Analysis (RTCA) DP
Instrument (ACEA Biosciences). This system allows impedance-based real-time
growth/proliferation measurements of adherent cells by measuring the net adhe-
sion/confluency (Cell Index) of cells to high-density gold electrodes on custom-
designed plates. The assay was performed according to the manufacturer’s guide-
lines. Specifically, 48 h after transfection of the cells with the respective siRNAs (as
described above), 20’000 cells were seeded into xCELLigence proliferation plates
(E-Plate 16 PET; ACEA Biosciences, 300600890) in complete growth medium and
monitored over 48 h with a measurement every 15 min. Four wells were measured
for each sample as technical replicas. The average Cell Index for each sample plus
standard deviation was calculated and plotted (for one measurement per hour over
48 h) by using the RTCA Software 2.1.0 (ACEA Biosciences).
Human xenografts in immunocompromised mice. Nude mice (Hsd:Athy-
micNude-Foxn1nu) were purchased from Harlan and housed under standard
conditions with free access to water and food at temperatures of 21–23 °C and
humidity of 40–60 %. Experiments were carried out with female mice of
6–10 weeks of age. Xenografts of human melanoma cells were generated by dis-
sociating cultured cells with PBS+ 2 mM EDTA to generate single-cell suspen-
sions, which were resuspended in 100 μl of RPMI-1640 medium and mixed 1:1
with Matrigel matrix (356234, BD Biosciences). A total volume of 200 μl of the cell-
matrigel mix was injected subcutaneously per injection site with a 1 ml syringe with
a 25-gauge hypodermic needle. For xenografts of siRNA-treated M010817 and
M150548 cells, 1’000’000 tumor cells were subcutaneously injected per injection
site and let grown for 6 days. For the generation of xenografts that were treated
with HDAC inhibitors, 300’000 M010817 cells were grafted subcutaneously per
injection site (two injections per mouse). Forteen days after cell injections, mice
carrying human xenografts were treated with 10 mg kg−1 body weight Panobino-
stat or 40 mg kg−1 body weight Mocetinostat or vehicle every second day for
2 weeks. In vivo HDACi treatment was performed similarly to previously estab-
lished protocols73–75. Specifically, Mocetinostat (MGCD0103; Selleckchem, S1122)
and Panobinostat (LBH589; Selleckchem, S1030) were diluted at 100 mg ml−1 and
25 mgml−1, respectively in DMSO (Sigma–Aldrich, D2650). Next, 10 µl of the
drugs dissolved in DMSO were diluted with 90 µl sunflower oil and the total
volume of 100 µl was injected i.p. for each treatment. Vehicle injections consisted of
10 ul DMSO (Sigma–Aldrich, D2650) diluted in 90 µl sunflower oil. Tumor length
and width were measured with a caliper and xenograft volumes calculated
according to the formula V ¼ 23 πxðaþb4 Þ3, as previously published76, wherein a
(mm) was the length and b (mm) was the width of the tumor. Tumor xenografts
(max ≤ 1 cm3 or at experimental endpoint) were harvested from euthanized mice
and for qRT-PCR-based gene expression analysis further processed as pre-
viously described for RNA isolation from murine lungs22. Briefly, dissected tumors
were submerged in 500 µl of TRIzol® reagent (15596026, ThermoFisher) and
homogenized with a tissue homogenizer (Polytron PT 2100, Kinematica) and RNA
extracted following the manufacturer’s guidelines. After extraction, 50 μg of RNA
were purified and treated with DNAse, respectively, with the RNeasy Mini Kit
(74104, Qiagen) and the RNase-Free DNase Set (79254, Qiagen). The reverse
transcription and qRT-PCR was further done, as described above.
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Corning® Transwell® migration assay. The migration assay was carried out
similarly to the manufacturer’s guidelines. Specifically, prior to seeding the cells
into the transwell migration chamber they were incubated in starvation medium
(RPMI+ 1% FBS, P/S, L-Glut) for 24 h. Next, 50,000 cells in 500 µl FBS-free
starvation medium were seeded per well onto the porous membrane of Clear
Transwell Inserts (Corning, 3464) and placed within a multi-well plate with 800 ul
of normal growth medium (RPMI+ 10% FBS+ P/S+ L-Glut) in the bottom of the
well. Cells in the transwell chambers were then incubated at 37 °C for 16 h. At the
experimental endpoint, inserts were taken out and remaining starvation medium in
the upper chamber was carefully pipetted up and down and then collected with the
nonmigratory cells in suspension, centrifuged, and cell pellets further processed for
RNA extraction. The medium with nonmigratory cells of three wells was pooled to
make one sample. Next, membranes now free of nonmigratory cells were cut out of
the flipped transwells and three membranes were collected in one Eppendorf to
make one sample and were further processed with lysis buffer to extract RNA of
migratory cells. RNA extraction and qRT-PCR were performed as described above.
Corning® Matrigel® invasion assay. The invasion assay was carried out similarly
to the manufacturer’s guidelines. Specifically, prior to seeding of the cells into the
invasion chamber, they were incubated in starvation medium (RPMI+ 1% FBS,
P/S, L-Glut) for 48 h. On the day of cell seeding, invasion plates with inserts
(Corning, 354480) were equilibrated by adding 800 ul blunt medium into the wells
and 500 ul into each insert and incubated for 2 h at 37 °C. Cells were then collected,
washed once in PBS, resuspended in starvation medium and seeded into each insert
in a final volume of 500 ul. Of the cell line M010817 200,000 cells were seeded, of
M070302 160,000 and of M150548 200,000 cells, respectively. Inserts were then
placed into wells where blunt medium was aspirated and replaced by 800 ul of
growth medium (RPMI+ 10% FBS+ P/S+ L-Glut) and seeded cells were incu-
bated for 24 h at 37 °C. For analysis, the medium in the inserts was aspirated and
the membrane cleaned carefully but vigorously with cotton swabs and washed once
with PBS. Cells were then fixed with 4% Roti Histofix (Carl Roth, P087.3) for
15 min at room temperature and washed once with PBS. Inserts were then carefully
cut out with a scalpel and placed downside up onto microscopy glass slides, cov-
ered with some drops of Fluorescent Mounting Medium (Dako, S3023) with 1:1000
Hoechst 33342 (Sigma–Aldrich, 14533) and covered with glass cover slips. Image
acquisition of the membranes with the invaded cells was done on a DMI 6000B
microscope (Leica). Cell counts were determined using ImageJ. Tile scans of whole
membranes were first set to 8 bit and inverted. The background was subtracted
using default settings of 50 and the threshold was adjusted (auto) and under binary
converted to a mask. Waterstedding was applied and a circle drawn (and saved as
ROI for subsequent analyses), wherein particles were analyzed with 50–700 pixel
size and 0.7–1.0% circularity. Same ROIs were used for analysis of membranes
within one experiment. Four technical replicas i.e. membranes were used per
experimental group. For HDAC inhibitor treatment in the invasion assay, the
drugs were added to the starvation medium in the top chamber as well as the FCS
high growth medium in the lower chamber for the whole duration of the assay at
600 nM (Mocetinostat) and 7 nM (Panobinostat) final concentrations. For siRNA
treatment in the invasion assay, cells were transfected with the respective siRNA
in vitro in normal growth medium (10 %) FCS. 24 h later, medium was exchanged
to starvation medium (1%). Again 24 h later, siRNA-treated cells were seeded into
the invasion chamber as described above and analyzed again 24 h later.
RNA sequencing. RNA sequencing of wild-type and hyperplastic murine mela-
nocytes was performed in the frame of the study of Varum et al. (2019)19 at the
iGE3 Genomics Platform Geneva, Switzerland. RNA quantity and integrity were
assessed with a Bioanalyzer (Agilent Technologies). Total RNA of 2 ng as input was
used for reverse transcription and cDNA amplification using the SMART-Seq v4
kit from Clontech according to the manufacturer’s instructions. 200 pg of cDNA
were then used for library preparation using the Nextera XT kit from Illumina.
Library molarity and quality was assessed with the Qubit and Tapestation using a
DNA High sensitivity chip (Agilent Technologies). Libraries were pooled at 2 nM
and loaded for clustering on 1 lane of a single-read Illumina flow cell. Reads of 50
bases were generated using the TruSeq SBS chemistry on an Illumina HiSeq
4000 sequencer. The reads were mapped with STAR aligner v.2.5.3a to the UCSC
Mus musculus mm10 reference genome and differential expression analysis was
performed with the statistical analysis R/Bioconductor package edgeR v.3.14.0.
Supplementary Data 1 contains the complete list of differentially expressed genes in
hyperplastic melanocytes compared to wild-type ones (with cutoffs for Log2
ratio ≥ 0.58 or ≤−0.58, p value < 0.05 and FDR < 0.05), of which the top 20 genes
are presented in Fig. 1b.
RNA sequencing of human melanoma cells with SALL4 knockdown was
performed at the Functional Genomics Center Zurich, Switzerland. Specifically,
total RNA of three experimental replicates of siControl and siSALL4 was isolated
using the RNAeasy Kit (74104, Qiagen) and RNase-Free DNase Set (79254,
Qiagen) according to the manufacturer’s protocol. On the Agilent RNA
ScreenTape assay and the Agilent 4200 TapeStation, quality control of total RNA
was performed. With magnetic beads poly-A mRNA was enriched (TruSeq RNA
Library Prep Kit v2) before cDNA synthesis and library preparation. After
sequencing on the Illumina HiSeq 4000 platform, RNA counts were quantified
from single-end reads using STAR aligner and mapped to the homo sapiens hg38
reference genome. Subsequent bioinformatic analysis of differentially expressed
genes was performed with DeSeq2 version 1.16.1. Gene ontology network analysis
was performed with MetaCoreTM (Thomson Reuters). Supplementary Data 2
contains the complete list of differentially expressed genes (with cutoffs for Log2
ratio ≥ 0.27 or ≤−0.27, p value < 0.05 and FDR < 0.05) used for the row z-score
heatmap and the MetaCoreTM analysis (also included in Supplementary Data 2) in
Fig. 4 a, b.
Immunocytochemistry. For stainings of adherent cells, culture medium was
aspirated from culture wells, cells washed with PBS (Thermo Fisher, 10010) and
fixed in 4 % Roti Histofix (Carl Roth, P087.3) for 15 min at room temperature.
Histofix was removed and cells washed three times for 5 min with PBS. Sections
were blocked for 50 min at room temperature in blocking buffer containing 1%
BSA (Sigma–Aldrich, 05470) and 0.2% Triton™ X-100 (Sigma–Aldrich, 9002-93-1)
in PBS. After aspirating the blocking buffer, primary antibodies were applied in
blocking buffer at the concentrations indicated in Supplementary Table 3 and
incubated for 1.5 h at room temperature. After washing the sections again 2× with
PBS, they were incubated with secondary antibodies in blocking buffer for 45 min
at room temperature. Cells were again washed 2× with PBS and finally, nuclei were
stained with Hoechst 33342 (Sigma–Aldrich, 14533) and slides were mounted with
Fluorescent Mounting Medium (Dako, S3023). Sections were imaged with a DMI
6000B microscope (Leica).
Gene Set Enrichment Analysis (GSEA). GSEA39 version 4.1.0 was run if there
was a minimum of 15 shared genes between the datasets to compare and on default
settings with 1000 permutations.
Co-immunoprecipitation. Co-immunoprecipitation experiments were performed
using the Dynabeads Co-Immunoprecipitation Kit (Thermo Fisher, 14321D) and
following the manufacturer’s instructions. In brief, 1.5 mg Dynabeads M-270
Epoxy per sample were initially washed with 1 ml of C1 solution. The beads were
collected using a magnet and then resuspended in 55 µl C1 solution+ 20 g anti-
body (either SALL4, abcam #ab29112, or IgG, abcam # ab6709 or Cell Signaling #
2729 S) and equal volume of C2 solution. The beads were then coupled overnight at
37 °C. The next day, the beads were washed with HB and LB solution (always
+0.01% Tween-20) respectively, and finally washed with and resuspended in SB
solution (as in manufacturer instructions).106 M010817 cells were harvested,
weighted and resuspended in Extraction buffer in a ratio 1:9 (+cOmplete, Mini,
EDTA-free Protease Inhibitor, Sigma #11836170001). Cells were lysed for 15 min
on ice, centrifuged at 2600 × g for 5 min at 4 °C and the supernatant was transferred
to a new tube. The antibody coupled beads were then washed with 900 µl of
Extraction buffer, collected with a magnet and gently resuspended in the cell lysate.
Coupled beads and cell lysate were incubated for 30 min at 4 °C on a rotator. The
beads were then washed for six times with the Extraction buffer, incubated 5 min at
RT in LWB buffer (+0.01% Tween-20) and finally 5 min at RT in elution buffer
(EB). The supernatant was then used to perform western blots and either 1% input
or 0.01% input were used as positive control for the pulldowns of SALL4 (1%) or of
HDACs (0.01%).
Cleavage under targets and release using nuclease (CUT&RUN) sequencing.
M010817 cells were harvested by adding EDTA to the cell medium to a final
concentration of 2 mM and by detaching cells by gentle scraping and pipetting.
Cells were then washed three times by pelleting at 300 × g for 5 min and resus-
pending in 2 ml wash buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 2 mM Sper-
midine, EDTA-free protease inhibitor) each time. Cells were counted, and 500,000
cells per sample were bound to 40 µl of Concanavalin A beads prepared according
to a previously established protocol77. Beads were divided into 2 ml tubes placed on
a magnetic rack. Beads were allowed to bind the magnet until clear (~2 min),
whereafter the supernatant was removed, and beads resuspended in 150 µl of
antibody buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 2 mM Spermidine, EDTA-
free protease inhibitor, 0.05% Digitonin, 2 mM EDTA). Antibodies (HDAC2:
Abcam ab12169 and Cell Signaling 57156 S; SALL4: Abcam ab29112 and
Antibodies-Online ABIN6132627; and FLAG: Sigma–Aldrich F1365) were added
at a 1:100 dilution to the respective samples. Cells were incubated overnight on a
rocking table at 4 °C. Next, cells were washed two times by binding beads to
magnetic rack, allowing to clear and resuspending in 1 ml digitonin-wash buffer
(20 mM HEPES pH 7.4, 150 mM NaCl, 2 mM Spermidine, EDTA-free protease
inhibitor, 0.025% Digitonin, 2 mM EDTA). Beads were then allowed to bind until
clear (~2 min), whereafter the supernatant was removed and beads resuspended in
100 µl of 0.5× CUTANA pA/G-MNase (EpiCypher) solution (20 mM HEPES pH
7.4, 150 mM NaCl, 2 mM Spermidine, EDTA-free protease inhibitor, 0.025%
Digitonin, 2 mM EDTA, 0.5× CUTANA). Next, the cells were incubated for 2,5 h
on a rocking table at 4 °C and then washed two times by binding the beads to a
magnetic rack, allowing to clear and resuspending in 1 ml digitonin-wash buffer.
Beads were allowed to bind until clear (~2 min), whereafter the supernatant was
removed and beads resuspended in 100 µl of digitonin-wash buffer. Next, tubes
were submerged in ice-water and allowed to chill for ~1 min before 2 µl of 100 mM
CaCl2 was added to each sample. To stop the reaction, 100 µl STOP buffer
(150 mM NaCl, 20 mM EDTA, 4 mM EGTA, 0.025% Digitonin, 100 µg/ml RNAse
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A, 50 µg/mL Glycogen, 100 pg/ml yeast spike-in DNA) was added to each tube.
Then, the tubes were placed in a 37 °C heat block for 30 min to release soluble
chromatin from cells. Beads were again bound to the magnetic rack and allowed to
clear completely, and the supernatant was transferred carefully into a DNA-lo
bind tube.
DNA was extracted using Phenol:Chloroform extraction and libraries were
prepared using KAPA HyperPrep Kit (Roche) using KAPA DUI adapters (Roche).
Libraries were pooled, and later sequenced on a NextSeq 500 using a NextSeq 500/550
High Output Kit v2.5 (75 Cycles), generating 36 bp paired-end FASTQ files. Reads
were trimmed using BBDuk, removing overrepresented repeat sequences (i.e., [TA]18,
[G]36), artifact, and adapter sequences. Reads were aligned to the human genome
(hg38) using bowtie78 with settings -X 700 -m1 -v 3. Duplicate reads were removed,
and files were sorted using samtools79. Mapped reads were filtered for size, keeping
only reads with a fragment size at or below 120 base pairs. Bedgraph files were
generated using bedtools genomecov, and peaks were called using SEACR version 1.3
(https://seacr.fredhutch.org/)80, in relaxed mode, normalizing to the negative control.
Single-gene tracks were visualized with the Integrative Genome Viewer (IGV) version
2.8.13 (https://software.broadinstitute.org/software/igv/download).
HDAC inhibitor treatment in vitro. With Mocetinostat (MGCD0103; Sell-
eckchem, S1122) and Panobinostat (LBH589; Selleckchem, S1030) stocks of 10 mM
drug in DMSO (Sigma–Aldrich, D2650) were generated and stored at −20 °C. For
working concentrations of 600 nM Mocetinostat and 7 nM Panobinostat, respec-
tively, stock solutions were further diluted in complete growth medium and added
to cells in culture for 48 h.
Chromatin immunoprecipitation of H3K27ac and sequencing. ChIP analysis
was performed as previously described81. Briefly, 1% formaldehyde was added to
cultured cells to crosslink proteins to DNA. Isolated nuclei were then lysed and
sonicated using a Bioruptor ultrasonic cell disruptor (Diagenode) to shear genomic
DNA to an average fragment size of 200 bp. Twenty micrograms of chromatin was
diluted to a total volume of 500 μl with ChIP buffer (16.7 mM Tris–HCl, pH 8.1,
167mM NaCl, 1.2 mM EDTA, 0.01% SDS, 1.1% Triton X-100) and precleared with
10 μl packed Sepharose beads for 2 h at 4 °C. Precleared chromatin was incubated
overnight with the indicated antibodies. The next day, Dynabeads protein-A were
added and incubated for 4 h at 4 °C. After washing, bound chromatin was eluted
with the elution buffer (1% SDS, 100mM NaHCO3). Upon proteinase K digestion
(50 °C for 3 h) and reversion of crosslinking (65 °C, overnight), DNA was purified
with phenol/chloroform, ethanol precipitated and quantified by QubitTM dsDNA
HS assay kit (Invitrogen). Library prep and sequencing was done at the Functional
Genomics Center Zürich (FGCZ) with 1–10 ng of total DNA. Libraries were gen-
erated at the FGCZ and sequencing was performed on Illumina HiSeq2500. All
sequence reads were mapped to the homo sapiens hg19 UCSC reference genome
using Bowtie2 (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml). Peak calling
was performed with the HOMER tool package version 4.11 (http://homer.ucsd.edu/
homer/) to find peaks in siCtrl and siSALL4 samples and significantly gained or lost
H3K27ac peaks in the siSALL4 versus siCtrl sample. Supplementary Data 7 contains
the list of significant peaks in both the siCtrl and siSALL4 samples and Supple-
mentary Data 8 contains the significantly gained and lost H3K27ac regions of
siSALL4 over siCtrl. Read density heatmaps for Figure 7a were generated with
HOMER and single tracks visualized with the Integrative Genome Viewer (IGV)
web application (https://igv.org/app/).
HAT inhibitor (CTK7A) treatment in vitro. With the Histone Acetyl Transferase
Inhibitor VII CTK7A (Calbiochem, 382115) stocks of 10 mgml−1 drug in DMSO
(Sigma–Aldrich, D2650) were generated and stored at −20 °C. For working con-
centrations of 50 µM CTK7A, stock solutions were further diluted in complete
growth medium and added to cells in culture for 48 h.
HDAC activator (ITSA-1) treatment in vitro. With the HDAC activator ITSA-1
(Santa Cruz, CAS 200626-61-5) stocks of 25 mgml−1 drug in DMSO
(Sigma–Aldrich, D2650) were generated and stored at 4 °C. For working con-
centrations of 100 µM ITSA-1, stock solutions were further diluted in complete
growth medium and added to cells in culture for 48 h.
Statistical analysis. All statistical evaluations (unpaired, two-tailed Student’s t-
tests) were done using GraphPad Prism 5.0 and Excel with p values > 0.05= n.s., p
values ≤ 0.05= *, p values ≤ 0.01= **, p values ≤ 0.001= ***. Experiments were
done in number of replicates as indicated for each figure.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The RNA seq datasets of hyperplastic and wild-type melanocytes from Varum et al. 2019
are available on the European Nucleotide Archive (ENA) under accession code
PRJEB30285. The RNA seq data of siControl and siSALL4-treated M010817 cells
generated for this study are available on ENA under the accession code PRJEB39208. The
ChIP-seq data of H3K27ac in siControl and siSALL4-treated M010817 cells generated for
this study are available on ENA under accession code PRJEB39209. The CUT&RUN seq
data of SALL4 and HDAC2 in M010817 cells generated for this study are available on
ArrayExpress under accession code E-MTAB-10163. The lists of differentially expressed
genes from RNA seq experiments or lists of called peaks from ChIP-seq and C&R seq
that resulted from our analysis of the deposited raw data are provided as Supplementary
Data with this paper. Source data are provided with this paper.
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